Bharath Krishnamurthy, a director of health policy and analytics at the American Hospital Association, explains the financial impact of current healthcare staffing shortages.
The drugmaker argues that the FDA's recent approval of a generic version of Entresto should not be allowed for multiple reasons. Novartis sent multiple requests to the agency hoping to stop the approval, but the FDA denied each one.
The new medical device correction only includes a select number of devices. Abbott said they produce inaccurate readings, putting patient health at risk.
The diabetes drug, sold by Eli Lilly and Company under the brand names Zepbound and Mounjaro, was associated with better outcomes, improved symptoms and more significant weight loss than a placebo.
Echocardiography vs CT for Prediction of Newly Created LVOT Area: (A-D) Newly created left ventricular outflow tract (neo-LVOT) assessment by echocardiography and (E-H) CT, both before and after valve implantation. Images courtesy of Bartkowiak et al., JACC: Cardiovascular Imaging.
LVOT obstruction after TMVR remains a significant concern among structural heart cardiologists. Predicting the risk of LVOT obstruction typically requires CT, which comes with certain disadvantages compared to other imaging options.
Dr. Masoud Pezeshkian speaking at the endorsement ceremony for Iranian president this week, with Iran's Supreme Leader Ayatollah Ali Khamenei. Photo courtesy off the Government of the Islamic Republic of Iran
Cardiac researcher Masoud Pezeshkian, MBBS, became one of the world's most widely known cardiac surgeons in the world when he officially became Iran's president.
Individuals are 83% more likely to be diagnosed with a psychiatric disorder within one year of a CVD hospitalization, according to new data published in the Journal of the American Heart Association.
This partnership reflects NextGen Healthcare’s deepening commitment to supporting cardiology practices nationwide. Research shows that nearly 50 percent of adults in the United States have some form of cardiovascular disease today—a rate expected to grow to 61 percent by 2050.
A team of Cleveland Clinic specialists tracked data from more than 13,000 patients, focusing on all-cause mortality and long-term cardiovascular outcomes.
